2607 — Shanghai Pharmaceuticals Holding Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Market Cap
HK$43.80bn
Enterprise Value
HK$69.71bn
Revenue
CNY275.25bn

Annual income statement for Shanghai Pharmaceuticals Holding Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	191,909	215,824	231,981	260,295	275,251
Cost of Revenue
Gross Profit	27,039	28,492	30,478	31,018	30,492
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	184,760	207,627	223,004	252,641	267,137
Operating Profit	7,150	8,197	8,977	7,655	8,114
Other Net Non Operating Costs
Net Income Before Taxes	7,175	8,144	8,808	7,054	8,020
Provision for Income Taxes
Net Income After Taxes	5,605	6,275	6,992	5,167	5,870
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,496	5,093	5,617	3,768	4,553
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,496	5,093	5,617	3,768	4,553
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.71	1.5	1.34	1.05	1.29
Dividends per Share